Laureate Institute for Brain Research
Trial Pipeline
LIFU Mechanisms for PTSD in Healthcare Workers
NCT07164105
Decoding Emotional Dynamics in Bipolar Disorder
NCT07221864
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
NCT07166289
Dose-Dependent Effects of Low-Intensity Focused Ultrasound
NCT07099950
Mood and Decision-making in Methamphetamine Use Disorder
NCT06410196
Interoceptive Mechanisms of Body Image Disturbance in Anorexia Nervosa
NCT06332963
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
NCT06088732
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
NCT06263660
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
NCT06004115
Amplification of Positivity for Alcohol Use
NCT06030154
Gastrointestinal Interoception in Anorexia Nervosa
NCT05111977
ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
NCT04724447
Neural Response to Inflammatory Challenge in Major Depressive Disorder
NCT04751331
Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)
NCT04426461
Self-regulation of Prefrontal Cortex During Emotional Cognitive Control
NCT04543500
Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response
NCT02807480
Effects of Reduced Environmental Stimulation on Eating Disorders
NCT02801084
Neurocognitive Predictors of Behavioral Therapy Response in Depression
NCT02602340
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for Laureate Institute for Brain Research Shows
According to the ClinicalTrials.gov registry, Laureate Institute for Brain Research is linked to 74 US clinical trials across every stage of research activity. Of those, 70 studies are currently recruiting — about 95% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 5% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Laureate Institute for Brain Research reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 32 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Laureate Institute for Brain Research is Depression with 5 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.